The human tetanus immunoglobulin market was valued at USD 1,061.0 Mn by 2019. Rising prevalence of tetanus prone injuries worldwide primarily drives the human tetanus immunoglobulin market growth. Furthermore, the provision of free and compulsory immunization of children and increasing public health awareness together accentuate the market growth.

Human tetanus immunoglobulin mainly comprises of immunoglobulin in which the concentration of specific IgG to tetanus toxin is close to 100 IU/ml in nominal 250 IU vials. It serves as immediate prophylaxis in patients who have acquired tetanus prone injuries and whose previous immunization is not clear. Furthermore, it is also widely employed in patients showing deficiency in antibody production or vaccinated patients having high-risk wounds.

The major segments related to the human tetanus immunoglobulin market are: 

By Demography (2017–2027; US$ Mn)

Adult

Children

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global human tetanus immunoglobulin market
• The overall segmentation of the Human Tetanus Immunoglobulin market, by demography, distribution channel, and geography is minutely studied. Adult and hospital pharmacy are dominating the demography and distribution channel segments respectively
• Growing incidence of tetanus infection worldwide
• Proactive role adopted by the government healthcare agencies across the globe for the compulsory immunization of tetanus immunoglobulin in children further accentuates the market growth

Report gist?

• The study of the global human tetanus immunoglobulin market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of demography and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of human tetanus immunoglobulin due to the  rising prevalence of tetanus infection worldwide
• The report will benefit healthcare professionals actively engaged in providing compulsory immunization to children across the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to human tetanus immunoglobulin market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Children are spearheading the demography segment for the human tetanus immunoglobulin market. Increasing public health awareness regarding the future benefits of prophylactic immunization and proactive role adopted by the government healthcare agencies in providing free immunization of human tetanus immunoglobulin to children across the globe together drive the market growth. Adult demography will be showcasing comfortable market growth during the forecast period owing to the growing incidence of tetanus infection among individuals working in cattle and dairy industries and compulsory immunization of researchers engaged in performing preclinical trials of new drug entity.

Hospital pharmacy is representing the largest market share in the distribution channel segment for the human tetanus immunoglobulin market. Increasing public health awareness regarding the compulsory immunization programs adopted by the government health agencies in the primary healthcare centers worldwide makes it imperative for precise compounding of the human tetanus immunoglobulin under the supervision of hospital pharmacists. Retail pharmacy is expected to cater to exemplary market performance in the near future on account of its ability to provide medical aid to people residing in remote locations.

The Asia Pacific is currently dominating the geography segment for the human tetanus immunoglobulin market. The growing incidence of tetanus infection among the adult population primarily drives the market growth in the region. As per the latest research citings presented by the World Health Organization (WHO), approximately 45% of the deaths in the neonates were associated with tetanus infection in the South Asia region. Proactive role adopted by the government healthcare agencies for the compulsory immunization of children to prevent future tetanus infection further accentuates the market growth in the region. North Africa is the global hotspot for tetanus infection, hence it presents a lucrative market opportunity for western giants to establish retail outlets and subsidiaries in the region. Additionally, the free medical aid and immunization program conducted by the Red Cross, United Nations, etc., in the sub-Saharan regions further increases the demand for human tetanus immunoglobulin. Europe is considered as the second-largest regional segment for human tetanus immunoglobulin on account of the domicile of key players such as Octapharma AG., Grifols SA., Kedrion S.p.A., CSL Behring, etc. Latin America is anticipated to be the fastest-growing regional segment for the human tetanus immunoglobulin market due to the rising prevalence of tetanus infection in the Amazon basin and developing healthcare infrastructure.